2
Teva Pharmaceuticals manufacturing site. Locally, Teva produces oral solid medicines and packaging. | Image Credit: © jetcityimage – stock.adobe.com
Teva Pharmaceutical Industries announced on May 27, 2025 that its investigational anti-interleukin-15 (IL-15) antibody, TEV-53408, has been granted Fast Track status by FDA (1). The treatment is intended for people with celiac disease who are on a gluten-free diet.
Such a diet—which must be kept strictly and lifelong—is currently the only treatment for celiac disease, a chronic, autoimmune disorder that is triggered by gluten and results in a range of mostly gastrointestinal symptoms (1). TEV-53408…